Ingersoll Rand

IR · NYSE

$78.59+$0.84 (+1.08%)TodayMarket closed · Oct 20, 7:32 PM ET

Prev close $77.75

IR analyst rating

BuyConsensus of 7 analysts over the last 12 months. 57% rate it a buy.

Strong buy0
Buy4
Hold3
Underperform0
Sell0

12-month price target · 17 analysts

Average $94.95 (+20.8% upside)

Low: $82.86
Now: $78.59
High: $114.45

Upgrades and downgrades

The latest rating actions, newest first

IR analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Evercore ISI Group	Aug 11, 2026	Maintains	In-Line	$84.00 → $93.00	64%
Baird	Aug 3, 2026	Maintains	Outperform	$103.00 → $109.00	57%
Stifel	Jul 20, 2026	Maintains	Hold	$85.00 → $84.00	61%
Morgan Stanley	Jun 3, 2026	Maintains	Equal-Weight	$92.00 → $80.00	68%
Citigroup	Apr 30, 2026	Maintains	Buy	$113.00 → $109.00	63%
Barclays	Apr 30, 2026	Maintains	Overweight	$100.00 → $95.00	65%
Wells Fargo	Apr 30, 2026	Maintains	Overweight	$90.00 → $88.00	51%
Stifel	Apr 14, 2026	Maintains	Hold	$101.00 → $90.00	61%
Citigroup	Apr 13, 2026	Maintains	Buy	$117.00 → $113.00	63%
Barclays	Apr 1, 2026	Maintains	Overweight	$111.00 → $100.00	65%

The case for and against

Updated Jan 19, 2026

Bull case

Ingersoll Rand achieved approximately $7.2 billion in revenue for 2024, reflecting strong demand across various sectors such as industrial, medical, and energy. Notably, regional orders surged, with high teens growth in the Americas and low double-digit growth in the APAC region, particularly driven by initiatives in China. The company reported a 16% increase in backlog, coupled with a year-to-date Book to Bill ratio of 1.07x, indicating robust order momentum and a positive outlook for 2026.

Bear case

Ingersoll Rand experienced a modest beat in its 2Q25 results but reduced its 2025 organic sales guidance due to lower tariff-related pricing, contributing to an 11.4% decline in its stock price. The company's adjusted EBITDA fell to $427.2 million, or 28.6% of sales, down from $436.2 million, or 29.7% of sales, in the previous year, reflecting declining margins influenced by organic volume flow-through and the impacts of recent acquisitions. Additionally, EBITDA margins for 2Q25 were reported at 27.0%, representing a 40 basis point year-over-year decrease, highlighting ongoing challenges in sustaining profitability amidst escalating operational costs.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.